Spoken Alpha
Enovis CORP
Enovis Corporation manufactures and distributes medical devices for orthopedic care across two segments: Prevention & Recovery products including bracing, therapy systems, and pain management devices used by healthcare professionals and patients; and Reconstructive products including surgical implants and instrumentation for joint replacement and limb reconstruction.
Enovis CORP is a Healthcare company operating in Medical Devices with a $1.07B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ENOV.
$ curl https://api.spokenalpha.com/v1/companies/ENOVFAQ
Spoken Alpha indexes ENOV's earnings call transcripts at https://spokenalpha.com/companies/ENOV. Each call links to attributed speakers and parsed analyst Q&A. Enovis CORP's own investor relations page is at https://ir.enovis.com/.
Enovis CORP (ENOV) held its most recent earnings call on 2026-08-06, covering fiscal Q2 2026.
Enovis CORP (ENOV) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $0.64 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $0.76 | $0.79 | -3.8% | $582.8M | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $0.89 | $0.81 | +9.9% | $589.2M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $0.95 | $0.81 | +17.3% | $575.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $0.75 | $0.65 | +15.4% | $548.9M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $0.79 | $0.74 | +6.8% | $564.5M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $0.81 | $0.74 | +9.5% | $558.8M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $0.98 | $0.92 | +7.0% | $561.0M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $0.73 | $0.61 | +19.7% | $505.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $0.62 | $0.59 | +5.1% | $525.2M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $0.50 | $0.48 | +4.2% | $516.3M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $0.79 | $0.74 | +6.8% | $455.0M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $0.56 | $0.54 | +3.7% | $417.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $0.61 | $0.52 | +17.3% | $428.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $0.44 | $0.38 | +15.8% | $406.2M | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $0.72 | $0.66 | +9.1% | $408.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $0.59 | $0.48 | +22.9% | $383.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.59 | $0.50 | +18.0% | $395.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $0.37 | $0.35 | +5.7% | $375.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-21 | $1.77 | $1.74 | +1.7% | $1.02B | — | — | EODHD |
Source: EODHD. ENOV reported actuals as published; sparse fields render as —.